Release date: 2018-03-08
Recently, G1 Therapeutics announced that it is actively evaluating the clinical trial data of trilaciclib for small cell lung cancer (SCLC) patients undergoing first-line chemotherapy. Trilaciclib is a potential first-class short-acting CDK4/6 inhibitor for the preservation of hematopoietic stem cells and enhances immune system function during chemotherapy (myeloprotection). G1 Therapeutics, a clinical-stage biopharmaceutical company, is developing cyclin-dependent kinases (CDKs) with a special focus on CDK4 and CDK6, a proven and promising anticancer therapeutic target.
Small cell lung cancer (SCLC) is a disease in which cancer cells form in lung tissue. About 10-15% of lung cancers are SCLC. Smoking or prolonged exposure to tobacco-burning smoke is an important cause of illness. Because of the rapid spread of small cell lung cancer, it is important to diagnose and get treatment as soon as possible. The standard treatment for SCLC is chemotherapy.
This double-blind, placebo-controlled trial enrolled SCLC subjects diagnosed as extensive. The trial randomized 77 untreated patients to a 1:1 ratio, and 75 patients received trilaciclib or placebo intravenously before each etoposide and carboplatin (EP) chemotherapy. medicine. Growth factors were obtained in all subjects, including granulocyte colony stimulating factor (G-CSF) and erythropoietin as well as transfusion support.
Data from Phase 2a clinical trials showed that trilaciclib reduced the clinically relevant consequences of chemotherapy-induced myelosuppression compared with placebo. The data also shows that trilaciclib is well tolerated. In addition, trilaciclib showed a good trend in overall response rate (ORR), duration of remission (DOR), and progression-free survival (PFS) compared with placebo.
Several important hematologic results showed that in the first cycle, patients with grade 4 neutropenia decreased by nearly 93%. The reduction rate in patients with febrile neutropenia was 67.9%. Patients with delayed chemotherapy cycles decreased by 41.6%. G1 Therapeutics plans to share this data with US and European regulators this year and explore the next steps in trilaciclib development.
â–² G1 Therapeutics R&D pipeline overview (Source: G1 Therapeutics official website)
"The data from this trial clearly show that trilaciclib protects the bone marrow and immune system from the damaging effects of chemotherapy," said Dr. Raj Malik, chief medical officer and senior vice president of research and development at G1 Therapeutics. "Furthermore, the trilaciclib shows the bone marrow. Preservation improves patient outcomes. Chemotherapy remains the cornerstone of cancer treatment, and trilaciclib has the potential to benefit many cancer patients."
“These data have laid a solid foundation for us to advance the development of trilaciclib and its final commercialization,†said Dr. Mark Velleca, CEO of G1 Therapeutics. “It is significant to combine trilaciclib with checkpoint inhibitor/chemotherapy. We believe Trilaciclib has the potential to be a backbone for a variety of cancer chemotherapy regimens, bringing significant benefits to patients."
We wish that the trial of trilaciclib will go smoothly and get listed soon, improving the quality of life for many cancer patients.
Reference materials:
[1] G1 Therapeutics official website
[2] G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Benefits in Patients with Small Cell Lung Cancer
Source: WuXi PharmaTech
Gantry Type Video Measuring Instrument
The gantry image measuring instrument can efficiently detect the contours, surface shapes, dimensions, angles, and positions of various workpieces. It is mainly used to measure the size and angle of parts and components that are difficult or impossible to measure with caliper and angle ruler, but play an important role in assembly. It can also be used to take pictures of some parts and components to analyze the causes of defects, especially for PCB boards, films, protective films, optical glass, electronics, large sheet metal parts, connectors, precision mechanical parts, electronic components, semiconductor components and other industries, It can achieve rapid and accurate detection in large quantities.
advantage:
1. Adopting a high-power industrial high-definition color CCD and a continuous automatic zoom depth lens with fixed frame position, the zoom rate does not require calibration, greatly improving work efficiency and measurement accuracy.
2. Images can be output to electronic computer software for surveying and mapping engineering storage. It can be used for photography, copying, and storage.
3. It can inspect the specifications of buried holes, pipe trenches, etc. on the upper surface of the tested object block. The image and color tone on the surface of the product workpiece can be clearly seen.
Gantry Type Video Measuring Instrument,Large Image Measuring Instrument,Large Video Measuring Instrument,Video Inspection System
Zhejiang dexun instrument technology co., ltd , https://www.dexunmeasuring.com